APA (7th ed.) Citation

Kim, S. J., Yoon, D. H., Kim, J. S., Kang, H. J., Lee, H. W., Eom, H., . . . Kim, W. S. (2020). Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Cancer Research and Treatment, 52(2), 374-387. https://doi.org/10.4143/crt.2019.198

Chicago Style (17th ed.) Citation

Kim, Seok Jin, et al. "Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial." Cancer Research and Treatment 52, no. 2 (2020): 374-387. https://doi.org/10.4143/crt.2019.198.

MLA (9th ed.) Citation

Kim, Seok Jin, et al. "Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial." Cancer Research and Treatment, vol. 52, no. 2, 2020, pp. 374-387, https://doi.org/10.4143/crt.2019.198.